Researchers reviewed how deubiquitinating enzymes, known as DUBs, play a critical role in cancer stem cells. These specific cells are often harder to treat because they help tumors grow and spread. The review found that DUBs protect important proteins from being broken down by the body, which allows these cancer cells to maintain their stem-like qualities.
Beyond just survival, these enzymes help cancer cells change their shape and metabolism. This process, called epithelial-mesenchymal transition, allows the cells to move and adapt to different environments. The study also found that DUBs and these cell-changing factors work together in a loop to strengthen the cancer's ability to persist.
Because these enzymes are so central to how cancer stem cells behave, they may be a target for future treatments. However, this research is a systematic review of biological mechanisms, not a clinical trial. It does not provide data on human drug trials or specific safety profiles for patients. It highlights a potential path for scientists to develop better ways to stop cancer growth.
